Evidence map›Paper›PMID 21247358›Full record

ReviewExpert opinion on emerging drugs2011

Emerging treatments for noise-induced hearing loss.

Naoki Oishi, Jochen Schacht

Open access · greenAbstract readReview
In one paragraph

Review in Expert opinion on emerging drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 3 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 3 syntheses or guidelines pooled it, 190 citations in OpenAlex.

  1. Pooled it
  2. Recent advances in hearing conservation programmes: A systematic review.The South African journal of communication disorders = Die Suid-Afrikaanse tydskrif vir Kommunikasieafwykings · 2020
    Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Hearing Loss and Oxidative Stress: A Comprehensive Review.Antioxidants (Basel, Switzerland) · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. NADPH Oxidase 3: Beyond the Inner Ear.Antioxidants (Basel, Switzerland) · 2024
    Review
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Naoki OishiKresge Hearing Research Institute, Medical Sciences Bldg I, 1150 West Medical Center Drive, Ann Arbor, MI 48109-5616, USA.
Jochen Schacht

Funding

PROTECTION FROM AMINOGLYCOSIDE OTOTOXICITYR01DC003685 · NIDCD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHACHT, JOCHEN · 1998 to 2013
$4.1M
NIDCD NIH HHS R01 DC003685
6 · The paper itself

Abstract

introductionApproximately 5% of the population worldwide suffers from industrial, military or recreational noise-induced hearing loss (NIHL) at a great economic cost and detriment to the quality of life of the affected individuals. This review discusses pharmacological strategies to attenuate NIHL that have been developed in animal models and that are now beginning to be tested in field trials. AREAS COVERED: The review describes the epidemiology, pathology and pathophysiology of NIHL in experimental animals and humans. The underlying molecular mechanisms of damage are then discussed as a basis for therapeutic approaches to ameliorate the loss of auditory function. Finally, studies in military, industrial and recreational settings are evaluated. Literature was searched using the terms 'noise-induced hearing loss' and 'noise trauma'. EXPERT OPINION: NIHL, in principle, can be prevented. With the current pace of development, oral drugs to protect against NIHL should be available within the next 5-10 years. Positive results from ongoing trials combined with additional laboratory tests might accelerate the time from the bench to clinical treatment.

Indexed as

AnimalsClinical Trials as TopicHearing Loss, Noise-InducedHumans

Identifiers

PMID21247358
PMCPMC3102156
OpenAlexW2062029090

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.